Pneumococcal Vaccines Market: Key Opportunities and Global Forecast From 2021-2027: Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.

Healthcare facilities are looking forward to expanding their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination

For instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to provide smartphones with an app to various healthcare facilities in northern Mozambique, Africa for a period of one year. The program received funds from GAVI and United States Agency for International Development (USAID) under mVacciNation pilot program. The app enables these healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, thereby improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

Request Sample of Report: https://www.worldwidemarketreports.com/sample/614893

Increasing collaborations among key players to develop and introduce new pneumococcal vaccines and ongoing clinical trial studies on pneumococcal vaccines are expected to drive the growth of the pneumococcal vaccines market. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signed an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae. This partnership would utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) to develop a novel vaccine.

Key players operating in the pneumococcal vaccines market include Pfizer, Sanofi, GSK, Merck, Eli Lilly, AstraZeneca, Abera, S K Chemicals, Beijing Minhai Biotechnology, Baxter, Biken, Celgene Corporation, Panacea Biotec, Serum Institute of India, Genentech, Genocea Biosciences, ImmunoBiology, Lupin, Nuron Biotech, Biogen, Valneva Austria, Sinovac

Pharmaceutical companies are reluctant to invest in the production of new vaccines, owing to very few returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange for a continuous supply of vaccines from vendors at sustainable prices for the long term.

In 2010, Pfizer entered into the AMC program and agreed to supply 300 Mn doses of PCV13 for pneumococcal disease. Subsequently, Pfizer entered into two additional agreements with the AMC expanding its commitment with an additional 440 Mn doses, for a total commitment of 740 Mn doses of PCV13 vaccine until 2027.

Request PDF Brochure of Research Report: https://www.worldwidemarketreports.com/quiry/614893

Moreover, in 2015, Pfizer reduced prices of four new dose vial presentations of PCV13, which was expected to be introduced under the AMC program in 2016. The prices were reduced by 20% per dose i.e., from US$ 3.30 per dose to US$ 3.10 per dose.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provides our diverse range of clients from across all industries with vital decision-making insights to plan and align their market strategies in line with current market trends.

Contact Us:
Mr. Shah
Worldwide Market Reports,
Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737
Email: sales@worldwidemarketreports.com

This release was published on openPR.